Crews clear rubble from the 70-acre site on South Main Street of the old Lima Locomotive Works in this photo provided by the Allen County Historical Society. Clark Equipment, the last tenant of the ...

Some software engineers are finding that AI is speeding up their work, but at a cost: it’s also accelerating them towards burnout. Siddhant Khare is one of those programmers. In an interview with ...

At least two Wall Street firms see good times ahead for TJX Cos. shares, despite a choppy stock market reaction to the Marshalls and T.J. Maxx parent's latest earnings Wednesday. Both Bernstein and ...

Apple’s installed base surpassed 2.5 billion devices, driving recurring monetization and ecosystem expansion across all major geographic regions. Q1 revenue reached $143.8 billion, up 16% ...

Macworld reports that a macOS Tahoe 26.2 update caused a critical bug where Time Machine backups consumed all available space on Apple Time Capsules. Attempting to fix the issue by erasing the Time ...

Koninklijke Ahold Delhaize N.V. remains a Buy with ~9% upside and a 6% shareholder yield, targeting annual returns above 15%. ADRNY demonstrates resilience with 3.2% same-store sales growth, robust ...

Topicus has slid hard from its highs, but its cash-flow compounding engine may still be running underneath the noisy headlines. Topicus sells niche, mission-critical software and grows by buying small ...

Topicus is a “10-year hold” candidate because it buys sticky vertical software businesses and reinvests cash into more compounding. It owns niche, mission-critical software with high switching costs, ...

Start by thinking about the dilemmas your people will face. by Erin Meyer At the beginning of my career, I worked for the health-care-software specialist HBOC. One day, a woman from human resources ...

NEW YORK, Feb 19 (Reuters) - Online telehealth company Hims & Hers Health, seeking growth drivers as its original sexual-health franchises matured, may have overstepped with a risky launch of ...

Vertex Pharmaceuticals is the leader in cystic fibrosis treatment. The company has also expanded into other areas in recent years, winning approval for two new drugs. 10 stocks we like better than ...